Willow Best Alternatives for Each Use Case

What Willow Offers and Where It Falls Short

Willow positions itself as a women-first GLP-1 telehealth service with asynchronous provider visits and monthly medication shipments. The platform prescribes semaglutide and, in some cases, tirzepatide through compounding pharmacies, bundled with nutritional guidance marketed toward female patients.

That framing has appeal. Women account for roughly 70% of anti-obesity medication prescriptions in the United States, according to a 2023 analysis of commercial claims data published in Obesity 1. A platform that acknowledges sex-specific differences in GLP-1 response, body composition targets, and hormonal context is addressing a genuine gap.

The limitations become visible on closer inspection. Willow's cash-pay model means no insurance billing, which prices out patients whose plans do cover Wegovy or Zepbound. Lab work is not always required before prescribing, which conflicts with Endocrine Society clinical practice guidelines recommending baseline metabolic panels, HbA1c, and hepatic function before initiating GLP-1 receptor agonist therapy [2]. The platform's formulary leans on compounded semaglutide, a product whose regulatory status shifted after the FDA announced resolution of the semaglutide shortage in late 2024 [3].

None of this makes Willow illegitimate. It does mean the platform occupies a specific lane, and patients outside that lane deserve alternatives matched to their actual clinical and financial situation.

How GLP-1 Telehealth Platforms Actually Differ

Not all GLP-1 telehealth is the same product in different packaging. The variables that matter most are medication source (brand-name vs. compounded), provider credential depth, lab requirements, insurance integration, and whether the platform addresses conditions beyond obesity.

Brand-name semaglutide (Wegovy) demonstrated 14.9% mean body weight loss versus 2.4% for placebo at 68 weeks in the STEP-1 trial (N=1,961) 4. Tirzepatide (Zepbound) showed 22.5% reduction at the 15 mg dose versus 3.1% for placebo at 72 weeks in SURMOUNT-1 (N=2,539) 5. These numbers come from FDA-approved formulations manufactured under strict cGMP standards. Compounded versions have not undergone the same phase III evaluation, and potency testing by independent labs has shown variable concentrations in compounded semaglutide products [6].

Dr. Caroline Apovian, co-director of the Center for Weight Management and Wellness at Brigham and Women's Hospital, has stated: "Patients deserve to know whether the medication they're injecting has been tested in rigorous clinical trials or compounded in a facility with far less regulatory oversight. That distinction matters for safety and efficacy."

The platform comparison below sorts alternatives by the use case each one handles best.

Best Alternative for Lowest Out-of-Pocket Cost

For patients whose primary constraint is price, compounding-focused platforms like Henry Meds and Hims/Hers currently offer the lowest monthly costs, typically ranging from $199 to $299 per month inclusive of medication and provider visits.

These prices reflect compounded semaglutide or tirzepatide, not brand-name drugs. The cost difference is substantial. Wegovy's list price sits at approximately $1,349 per month without insurance 7. Zepbound lists near $1,060 monthly. Compounded alternatives drop that to a fraction, but patients accept trade-offs in standardized dosing and regulatory certainty.

Willow's pricing falls in a similar range to these competitors. The differentiator is not cost but rather what clinical infrastructure surrounds that cost. A platform charging $249 per month with mandatory quarterly labs, provider video visits, and metabolic tracking delivers more clinical value per dollar than one charging $199 with asynchronous chat alone.

If cost is truly the deciding factor, compare the total annual expense: medication, provider fees, required labs, and any hidden charges for dose adjustments. Some platforms advertise low base prices but charge separately for titration changes or provider consultations.

Best Alternative for Rigorous Clinical Oversight

Patients who want the closest thing to an in-person obesity medicine practice delivered remotely should evaluate platforms like Calibrate and Found, which build structured programs around GLP-1 prescriptions.

Calibrate requires baseline bloodwork including a comprehensive metabolic panel, lipid panel, and HbA1c before prescribing. The platform pairs patients with board-certified physicians (not nurse practitioners alone) and includes a year-long metabolic health curriculum. This model aligns more closely with the 2023 American Association of Clinical Endocrinology (AACE) obesity management guidelines, which recommend multi-component interventions combining pharmacotherapy with behavioral modification and ongoing metabolic monitoring [8].

Found takes a similar approach with required labs and a structured coaching program, though its provider network includes a mix of physicians and nurse practitioners.

Willow's clinical model, by comparison, relies more heavily on asynchronous encounters. For a patient with comorbid type 2 diabetes, PCOS, or cardiovascular risk factors, the depth of clinical oversight matters. The SELECT trial (N=17,604) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease 9. Capturing that cardiovascular benefit requires proper patient selection, baseline risk stratification, and ongoing monitoring. A platform that skips these steps may prescribe the same molecule but deliver a fundamentally different standard of care.

Best Alternative for Insurance-Covered GLP-1 Medications

Roughly 40% of large employer plans now include some coverage for anti-obesity medications, according to data from the Employer Health Benefits Survey 10. Patients with qualifying insurance should consider platforms that bill insurance directly rather than defaulting to cash-pay.

Ro and Sequence (now part of WW) both offer insurance navigation for brand-name Wegovy and Zepbound prescriptions. These platforms handle prior authorization paperwork, appeal denials, and coordinate with specialty pharmacies that stock FDA-approved formulations.

Dr. Fatima Cody Stanford, an obesity medicine physician at Massachusetts General Hospital, has noted: "The single biggest barrier to GLP-1 access is not the prescription itself but insurance coverage and prior authorization. Any platform that helps patients overcome that barrier is providing real clinical value beyond the medication."

Willow does not bill insurance. That is a deliberate business decision, not an oversight. Cash-pay models avoid the administrative burden of prior authorizations and denials. But for the patient whose plan covers Wegovy at a $25 copay, paying $300 per month out of pocket for a compounded version represents a poor financial decision with potential clinical trade-offs.

Before choosing any cash-pay platform, call your insurer. Ask specifically whether your plan covers semaglutide (Wegovy) or tirzepatide (Zepbound) for obesity, what the prior authorization requirements are, and which pharmacies are in network.

Best Alternative for Compounded Peptides Beyond Semaglutide

Some patients seek access to peptides beyond standard GLP-1 receptor agonists. BPC-157, AOD-9604, tesamorelin, and other research compounds have generated interest in the weight management and wellness space, though most lack FDA approval for obesity indications.

Platforms like Defy Medical and HealthRX offer broader peptide formularies under physician supervision with required lab monitoring. Tesamorelin, for example, holds FDA approval for HIV-associated lipodystrophy and has shown reductions in visceral adipose tissue of 15.2% over 26 weeks in its key trial 11. Its off-label use in general obesity remains investigational.

Willow's formulary centers on GLP-1 agonists. Patients interested in combination protocols involving growth hormone secretagogues, thyroid peptides, or other investigational compounds will need a platform with a wider prescribing scope and providers experienced in peptide therapy risk management.

The critical question for any peptide platform is whether a licensed physician reviews labs, screens for contraindications, and adjusts dosing based on objective biomarkers. A platform that ships peptides without this infrastructure is a supplier, not a clinic.

Best Alternative for Integrated Women's Hormone Therapy

Willow markets itself as women's health focused, but its primary product is GLP-1 prescriptions. Women navigating perimenopause or postmenopause who need both anti-obesity pharmacotherapy and hormone replacement therapy (HRT) may find Willow's scope too narrow.

Estrogen decline during menopause accelerates visceral fat accumulation and worsens insulin resistance. A 2022 meta-analysis of 23 randomized controlled trials (N=2,840) published in Menopause found that menopausal hormone therapy reduced visceral fat by a standardized mean difference of 0.41 (95% CI: 0.25 to 0.57) 12. Combining HRT with GLP-1 therapy addresses both the hormonal driver and the metabolic consequence of menopause-related weight gain.

Platforms like Midi Health and Alloy specialize in menopause care with prescribing capabilities for estradiol, progesterone, testosterone, and DHEA alongside metabolic medications. HealthRX integrates GLP-1 prescribing with full hormone panels, including estradiol, progesterone, free and total testosterone, SHBG, DHEA-S, and thyroid function.

For a 52-year-old woman with a BMI of 33, hot flashes, poor sleep, and rising HbA1c, a platform that prescribes semaglutide without evaluating her estradiol level is treating a symptom while ignoring its metabolic context. The North American Menopause Society (NAMS) 2022 position statement supports individualized HRT for symptomatic women within 10 years of menopause onset [13], and the metabolic benefits of estrogen replacement create a rationale for combined therapy.

Red Flags to Watch on Any GLP-1 Telehealth Platform

Not every telehealth platform prescribing GLP-1s meets a reasonable standard of care. Certain patterns should trigger caution regardless of the brand name.

No lab requirements before prescribing is the first warning sign. GLP-1 receptor agonists are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). The FDA prescribing information for semaglutide carries a boxed warning about thyroid C-cell tumors based on rodent studies [14]. A platform that prescribes without screening for thyroid history, pancreatitis history, or renal function is cutting clinical corners.

Guaranteed prescriptions before evaluation is another red flag. Any platform promising a GLP-1 prescription before a provider assesses the patient is operating as a pharmacy storefront, not a medical practice. Legitimate obesity medicine requires a BMI of 30 or greater (or 27 with a weight-related comorbidity) per FDA labeling criteria [15].

Absence of dose titration protocols raises risk. Semaglutide requires gradual titration from 0.25 mg weekly to the maintenance dose of 2.4 mg over 16 to 20 weeks to minimize gastrointestinal side effects. Platforms that start patients at higher doses or lack structured titration schedules increase the likelihood of nausea, vomiting, and treatment discontinuation. In STEP-1, gastrointestinal events occurred in 74.2% of the semaglutide group, though most were mild to moderate and concentrated during dose escalation 4.

How to Choose the Right Platform for Your Situation

The decision tree is simpler than the marketing noise suggests. Start with three questions.

Does your insurance cover Wegovy or Zepbound? If yes, use a platform that bills insurance and handles prior authorizations. The monthly savings can exceed $1,000.

Do you need hormone therapy alongside weight management? If yes, choose a platform with prescribing capabilities across GLP-1s, estradiol, progesterone, testosterone, and thyroid medications under one clinical team. Fragmented care across multiple telehealth providers creates gaps in drug interaction screening and metabolic monitoring.

Is your primary goal the lowest possible monthly cost? If yes, a compounding-focused platform may work, but verify that the platform requires labs, provides structured titration, and uses a licensed 503B outsourcing facility rather than a 503A pharmacy. The FDA distinguishes between these facility types based on manufacturing standards and oversight requirements [16].

Willow serves a specific patient: a woman who wants a GLP-1 prescription through a women-branded telehealth experience and is comfortable with cash-pay compounded medications. That is a valid choice for some. For patients who need deeper clinical oversight, insurance navigation, hormone integration, or broader peptide access, the alternatives above map to those needs directly.

Schedule baseline labs (CMP, HbA1c, lipid panel, TSH, and estradiol if perimenopausal) before your first visit with any platform. Arrive with data, not just a credit card.